Kirkland & Ellis advised AIM ImmunoTech on the deal. AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here